Skip to main content
Premium Trial:

Request an Annual Quote

Olivier Elemento and Anshul Kundaje

Freenome has announced the formation of its scientific advisory board including inaugural members Olivier Elemento and Anshul Kundaje.

Elemento is director of the Englander Institute for Precision Medicine, head of the Cancer Systems Biology Laboratory, and associate professor of computational genomics in computational biomedicine at Weill Cornell Medical College. He also serves as co-assistant dean for scientific computing, associate director of the Institute for Computational Biomedicine, and co-chair of the Genetics, Epigenetics and Systems Biology Program at the Meyer Cancer Center. 

Kundaje is an assistant professor of genetics and computer science at Stanford University, focused on computational regulatory genomics. He previously led integrative analysis efforts for the ENCODE Project and the Roadmap Epigenomics Project. 

According to Freenome, the new SAB will work closely with the company's management team to advance the development of the firm's technology platform and commercial disease screening products.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.